Literature DB >> 15121014

Stimulation of cAMP production and cyclooxygenase-2 by prostaglandin E(2) and selective prostaglandin receptor agonists in murine osteoblastic cells.

Yoko Sakuma1, Ziaodong Li, Carol C Pilbeam, Cynthia B Alander, Daichi Chikazu, Hiroshi Kawaguchi, Lawrence G Raisz.   

Abstract

Prostaglandins (PGs), particularly PGE(2), can stimulate bone resorption and formation and auto-amplify their effects by inducing cyclooxygenase (COX)-2. We examined the role of different PG receptors in stimulating cAMP production and COX-2 expression in murine calvarial osteoblasts. Cells were obtained from PGE(2) receptor (EP2R and EP4R) wild-type and knockout (KO) mice and from mice transgenic for the COX-2 promoter fused to a luciferase reporter. We analyzed effects of selective agonists, EP2A and EP4A, for EP2R and EP4R, which mediate the increase in cAMP in response to PGE(2). We also tested agonists for other PGE(2) receptors (EP1A and EP3A) and for prostacyclin (IPA), prostaglandin D(2) (DPA), thromboxane (TPA), and prostaglandin F(2alpha) (FPA) receptors. PGE(2) and EP2A were the most effective stimulators of cAMP production. EP4A, IPA, and DPA produced smaller responses, and EP1A, EP3A, FPA, and TPA were ineffective. In EP2R KO cells, cAMP responses to PGE(2) were reduced by 80%, and responses to EP2A were abrogated. In EP4R KO cells, cAMP responses to PGE(2) and EP2A showed a small reduction, while the response to EP4A was abrogated. Pretreatment with PGE(2), EP2A, or EP4A down-regulated the subsequent response to the respective ligands. COX-2 induction was measured by increased luciferase activity and mRNA expression. PGE(2) was the most effective agonist; EP2A and another selective EP2R agonist, butaprost, showed similar efficacy, and EP4A was less effective. EP2A and EP4A effects on luciferase activity were additive, and effects of the combination were similar to PGE(2) itself. IPA, TPA, and DPA produced 2- to 6-fold increases in COX-2 expression. FPA was a weak agonist, while EP1A and EP3A were inactive. Treatment with specific inhibitors indicated that PGE(2), EP2A, and EP4A induced COX-2 expression largely through protein kinase A (PKA). We conclude that the PG induction of COX-2 in this system generally paralleled effects on cAMP production and was mediated predominantly via the PKA pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15121014     DOI: 10.1016/j.bone.2003.12.007

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  13 in total

1.  Effects of selective prostaglandins E2 receptor agonists on cultured calvarial murine osteoblastic cells.

Authors:  Cynthia B Alander; Lawrence G Raisz
Journal:  Prostaglandins Other Lipid Mediat       Date:  2006-10-20       Impact factor: 3.072

2.  Teriparatide (human PTH1-34) compensates for impaired fracture healing in COX-2 deficient mice.

Authors:  Kiminori Yukata; Chao Xie; Tian-Fang Li; Matthew L Brown; Tsukasa Kanchiku; Xinping Zhang; Hani A Awad; Edward M Schwarz; Christopher A Beck; Jennifer H Jonason; Regis J O'Keefe
Journal:  Bone       Date:  2018-02-03       Impact factor: 4.398

3.  Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB.

Authors:  Teresa Morgan; Gerald J Atkins; Melanie K Trivett; Sandra A Johnson; Maya Kansara; Stephen L Schlicht; John L Slavin; Paul Simmons; Ian Dickinson; Gerald Powell; Peter F M Choong; Andrew J Holloway; David M Thomas
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

4.  Effects of prostaglandin E2 and lipopolysaccharide on osteoclastogenesis in RAW 264.7 cells.

Authors:  H Kaneko; M Mehrotra; C Alander; U Lerner; C Pilbeam; L Raisz
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2007-10-24       Impact factor: 4.006

5.  Effect of deletion of the prostaglandin EP2 receptor on the anabolic response to prostaglandin E2 and a selective EP2 receptor agonist.

Authors:  Shilpa Choudhary; Cynthia Alander; Peili Zhan; Qi Gao; Carol Pilbeam; Lawrence Raisz
Journal:  Prostaglandins Other Lipid Mediat       Date:  2008-02-29       Impact factor: 3.072

6.  In vitro and in vivo evidence for stimulation of bone resorption by an EP4 receptor agonist and basic fibroblast growth factor: Implications for their efficacy as bone anabolic agents.

Authors:  M E Downey; L S Holliday; J I Aguirre; T J Wronski
Journal:  Bone       Date:  2008-10-25       Impact factor: 4.398

Review 7.  Prostaglandins in bone: bad cop, good cop?

Authors:  Katherine A Blackwell; Lawrence G Raisz; Carol C Pilbeam
Journal:  Trends Endocrinol Metab       Date:  2010-01-14       Impact factor: 12.015

8.  Compensatory cellular reactions to nonsteroidal anti-inflammatory drugs on osteogenic differentiation in canine bone marrow-derived mesenchymal stem cells.

Authors:  Namgil Oh; Sangho Kim; Kenji Hosoya; Masahiro Okumura
Journal:  J Vet Med Sci       Date:  2014-01-13       Impact factor: 1.267

9.  Prostacyclin suppresses twist expression in the presence of indomethacin in bone marrow-derived mesenchymal stromal cells.

Authors:  Oliver Kemper; Monika Herten; Johannes Fischer; Marcel Haversath; Sascha Beck; Tim Classen; Sebastian Warwas; Tjark Tassemeier; Stefan Landgraeber; Sabine Lensing-Höhn; Rüdiger Krauspe; Marcus Jäger
Journal:  Med Sci Monit       Date:  2014-11-10

10.  Prostaglandin E2 acts via bone marrow macrophages to block PTH-stimulated osteoblast differentiation in vitro.

Authors:  Shilpa Choudhary; Katherine Blackwell; Olga Voznesensky; Abhijit Deb Roy; Carol Pilbeam
Journal:  Bone       Date:  2013-04-29       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.